There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunic (IMUX – Research Report) and Achilles Therapeutics (ACHL – Research Report) with bullish sentiments.
Immunic (IMUX)
Aegis Capital analyst Nathan Weinstein maintained a Buy rating on Immunic on August 8 and set a price target of $35.00. The company’s shares closed last Tuesday at $5.02.
According to TipRanks.com, Weinstein is ranked 0 out of 5 stars with an average return of
Immunic has an analyst consensus of Strong Buy, with a price target consensus of $31.60, implying a 539.7% upside from current levels. In a report issued on August 4, Wedbush also reiterated a Buy rating on the stock with a $11.00 price target.
See the top stocks recommended by analysts >>
Achilles Therapeutics (ACHL)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $3.00, close to its 52-week low of $1.84.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Achilles Therapeutics.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMUX:
- D.A. Davidson Sticks to Its Buy Rating for WW International (WW)
- Cantor Fitzgerald Reaffirms Their Buy Rating on WM Technology (MAPS)
- Stifel Nicolaus Sticks to Their Hold Rating for RealReal (REAL)
- Investors unimpressed with IWG revenue growth amid recession fears
- Similarweb Surpasses Q2 Expectations, but Loss Widens Year-over-Year
